Enochian Biosciences Investor Presentation Deck
January 2024, 28 slides
  1. Enochian Biosciences
  2. Related Decks
  3. Investor Presentation Decks
oncology platform overview | Enochian Biosciences
cautionary statement forward looking statements | Enochian Biosciences
vision freedom from toxic chemotherapy for solid tumors in our lifetime initial focus on tumors with poor longevity to provide hope for those without hope and to facilitate rapid progression through the regulatory process intent to pursue accelerated approvals by end early | Enochian Biosciences
solid tumors equivalent to of cancers solid tumors with poor longevity cancer cancer breast | Enochian Biosciences
cell and gene platforms engineered dendritic cell therapeutic vaccine solid tumors engineered cell therapeutic vaccine | Enochian Biosciences
leading efficacy for therapeutic vaccines in preclinical models for human solid tumors treated animals compared to controls | Enochian Biosciences
expanding preclinical testing in various solid tumors and disease progression stages | Enochian Biosciences
is a true platform for personalized precision medicine drug substance off the shelf ready to pulse with any tumor type infectious disease agent multiple flexibilities in manufacturing final drug products including future universal cancer antigens for true off the shelf products can be combined with other cancer therapies chemotherapy immune inhibitors exploring other indications in oncology infectious diseases | Enochian Biosciences
dendritic cells are the professional antigen presenting cells key to adaptive immunity an essential part of cancer and infectious disease fighting immunity dendritic cells orchestrate the immune response by presenting pieces of a tumor antigens to stimulate a reaction training immune cells to recognize and eliminate diseased cells and pathogens | Enochian Biosciences
tumor cells can evade normal immune response | Enochian Biosciences
| Enochian Biosciences
wae by a | Enochian Biosciences
manufacturing process facilitates scale up and patient access | Enochian Biosciences
procedural flow patient manufacturing site patient | Enochian Biosciences
humanized mouse model closely replicates human immune system | Enochian Biosciences
treatment significantly reduced size of pancreatic tumors in humanized mice in five independent studies two representative studies below | Enochian Biosciences
outperformed genetically unmodified dendritic cells approach mostly used by | Enochian Biosciences
treated mice showed no signs of metastatic disease | Enochian Biosciences
| Enochian Biosciences
| Enochian Biosciences
activates recognized maker of cancer killing spleen | Enochian Biosciences
| Enochian Biosciences
| Enochian Biosciences
clinical target product profile | Enochian Biosciences
initial clinical study phase i open to all solid tumors focus on patients with pancreatic cancer phase i safety assessment ascending dose ranging cohort of up to patients dose level phase enrollment starting in late fixed dose cohort design one cohort cancer type assumes high response rate up to patients extending cohort into assuming responding tumor type seek breakthrough and or designation for accelerated development and approval data to support available end first half of | Enochian Biosciences
study strategy companies often the full study to a cro there are large costs associated with layers of project management in this model and risks to meeting regulatory requirements by ceding full control initial estimates based upon prior experience with the full service cro model aggregated to approximately million for the phase i study by adopting a model where assumes more of the project management and parses out responsibility to vendors focusing on their strengths without their overhead costs budget reduced by an estimated while maintaining full control and full service | Enochian Biosciences
| Enochian Biosciences
thank you | Enochian Biosciences
See More
Enochian Biosciences
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Cancer
Manufacturing
Liver
Solid tumor
Recent decks by Enochian Biosciences
Results
August 2023
Investor Presentation
October 2022
See all presentations by Enochian Biosciences (3 decks)
Related decks
Fusion Pharmaceuticals
Investor Presentation
January 2024
BioNTech
Results
November 2021
TScan Therapeutics
IPO
July 2021
BioNTech
Investor Day
June 2022
Immatics
Investor Presentation
November 2023
BioNTech
Results
May 2021
Mink Therapeutics
IPO
October 2021
BioNTech
Results
March 2021
Recent decks by Enochian Biosciences
See all presentations (3 decks)
Results
August 2023
Investor Presentation
October 2022
Fusion Pharmaceuticals
Investor Presentation
January 2024
BioNTech
Results
November 2021
TScan Therapeutics
IPO
July 2021
BioNTech
Investor Day
June 2022
Immatics
Investor Presentation
November 2023
BioNTech
Results
May 2021
Mink Therapeutics
IPO
October 2021
BioNTech
Results
March 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io